Multivalent Vaccines Market Report

Global and Region Multivalent Vaccines Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 31, 2022
  • PAGES：179
  • REPORT CODE：GMM933753
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Multivalent Vaccines market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Multivalent Vaccinesmarket, defines the market attractiveness level of Multivalent Vaccines market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Multivalent Vaccines industry, describes the types of Multivalent Vaccines market, the applications of major players and the market size, and deeply analyzes the current situation of the global Multivalent Vaccines market and the development prospects and opportunities of Multivalent Vaccines industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Multivalent Vaccines market in Chapter 13.

    By Player:

    • GlaxoSmithKline, plc (UK)

    • Johnson & Johnson (US)

    • Protein Sciences Corporation (US)

    • CSL Limited (Australia)

    • Daiichi Sankyo (Japan)

    • Serum Institute of India Pvt Ltd (India)

    • Pfizer, Inc (US)

    • Emergent BioSolutions, Inc (US)

    • MedImmune, LLC (US)

    • Merck & Co, Inc (US)

    • Astellas Pharma Inc (Japan)

    • Mitsubishi Tanabe Pharma Corporation (Japan)

    • Bavarian Nordic (Denmark)

    • Sanofi Pasteur SA (France)

    • Panacea Biotec (India)

    By Type:

    • Conjugate Vaccines

    • Inactivated and Subunit Vaccines

    • Live Attenuated Vaccines

    • Toxoid Vaccines

    • Recombinant Vaccines

    By End-User:

    • Pediatrics

    • Adults

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Multivalent Vaccines Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Multivalent Vaccines Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Multivalent Vaccines Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Multivalent Vaccines Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Multivalent Vaccines Market Analysis and Outlook to 2022

    • 7.1 Global Multivalent Vaccines Consumption (2017-2022)

    • 7.2 United States Multivalent Vaccines Consumption (2017-2022)

    • 7.3 Europe Multivalent Vaccines Consumption (2017-2022)

    • 7.4 China Multivalent Vaccines Consumption (2017-2022)

    • 7.5 Japan Multivalent Vaccines Consumption (2017-2022)

    • 7.6 India Multivalent Vaccines Consumption (2017-2022)

    • 7.7 South Korea Multivalent Vaccines Consumption (2017-2022)

    8 Region and Country-wise Multivalent Vaccines Market Analysis and Outlook to 2028

    • 8.1 Global Multivalent Vaccines Consumption Forecast (2022-2028)

    • 8.2 United States Multivalent Vaccines Consumption Forecast (2022-2028)

    • 8.3 Europe Multivalent Vaccines Consumption Forecast (2022-2028)

    • 8.4 China Multivalent Vaccines Consumption Forecast (2022-2028)

    • 8.5 Japan Multivalent Vaccines Consumption Forecast (2022-2028)

    • 8.6 India Multivalent Vaccines Consumption Forecast (2022-2028)

    • 8.7 South Korea Multivalent Vaccines Consumption Forecast (2022-2028)

    9 Global Multivalent Vaccines Market Outlook by Types and Applications to 2022

    • 9.1 Global Multivalent Vaccines Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Conjugate Vaccines Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Inactivated and Subunit Vaccines Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Live Attenuated Vaccines Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Toxoid Vaccines Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Recombinant Vaccines Consumption and Growth Rate (2017-2022)

    • 9.2 Global Multivalent Vaccines Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Pediatrics Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Adults Consumption and Growth Rate (2017-2022)

    10 Global Multivalent Vaccines Market Outlook by Types and Applications to 2028

    • 10.1 Global Multivalent Vaccines Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Conjugate Vaccines Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Inactivated and Subunit Vaccines Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Live Attenuated Vaccines Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Toxoid Vaccines Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global Recombinant Vaccines Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Multivalent Vaccines Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Pediatrics Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Adults Consumption Forecast and Growth Rate (2022-2028)

    11 Global Multivalent Vaccines Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Multivalent Vaccines Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Multivalent Vaccines Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Multivalent Vaccines Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Multivalent Vaccines Market Competitive Analysis

    • 14.1 GlaxoSmithKline, plc (UK)

      • 14.1.1 GlaxoSmithKline, plc (UK) Company Details

      • 14.1.2 GlaxoSmithKline, plc (UK) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 GlaxoSmithKline, plc (UK) Multivalent Vaccines Product and Service

    • 14.2 Johnson & Johnson (US)

      • 14.2.1 Johnson & Johnson (US) Company Details

      • 14.2.2 Johnson & Johnson (US) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Johnson & Johnson (US) Multivalent Vaccines Product and Service

    • 14.3 Protein Sciences Corporation (US)

      • 14.3.1 Protein Sciences Corporation (US) Company Details

      • 14.3.2 Protein Sciences Corporation (US) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Protein Sciences Corporation (US) Multivalent Vaccines Product and Service

    • 14.4 CSL Limited (Australia)

      • 14.4.1 CSL Limited (Australia) Company Details

      • 14.4.2 CSL Limited (Australia) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 CSL Limited (Australia) Multivalent Vaccines Product and Service

    • 14.5 Daiichi Sankyo (Japan)

      • 14.5.1 Daiichi Sankyo (Japan) Company Details

      • 14.5.2 Daiichi Sankyo (Japan) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Daiichi Sankyo (Japan) Multivalent Vaccines Product and Service

    • 14.6 Serum Institute of India Pvt Ltd (India)

      • 14.6.1 Serum Institute of India Pvt Ltd (India) Company Details

      • 14.6.2 Serum Institute of India Pvt Ltd (India) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Serum Institute of India Pvt Ltd (India) Multivalent Vaccines Product and Service

    • 14.7 Pfizer, Inc (US)

      • 14.7.1 Pfizer, Inc (US) Company Details

      • 14.7.2 Pfizer, Inc (US) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Pfizer, Inc (US) Multivalent Vaccines Product and Service

    • 14.8 Emergent BioSolutions, Inc (US)

      • 14.8.1 Emergent BioSolutions, Inc (US) Company Details

      • 14.8.2 Emergent BioSolutions, Inc (US) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Emergent BioSolutions, Inc (US) Multivalent Vaccines Product and Service

    • 14.9 MedImmune, LLC (US)

      • 14.9.1 MedImmune, LLC (US) Company Details

      • 14.9.2 MedImmune, LLC (US) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 MedImmune, LLC (US) Multivalent Vaccines Product and Service

    • 14.10 Merck & Co, Inc (US)

      • 14.10.1 Merck & Co, Inc (US) Company Details

      • 14.10.2 Merck & Co, Inc (US) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Merck & Co, Inc (US) Multivalent Vaccines Product and Service

    • 14.11 Astellas Pharma Inc (Japan)

      • 14.11.1 Astellas Pharma Inc (Japan) Company Details

      • 14.11.2 Astellas Pharma Inc (Japan) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Astellas Pharma Inc (Japan) Multivalent Vaccines Product and Service

    • 14.12 Mitsubishi Tanabe Pharma Corporation (Japan)

      • 14.12.1 Mitsubishi Tanabe Pharma Corporation (Japan) Company Details

      • 14.12.2 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Product and Service

    • 14.13 Bavarian Nordic (Denmark)

      • 14.13.1 Bavarian Nordic (Denmark) Company Details

      • 14.13.2 Bavarian Nordic (Denmark) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 Bavarian Nordic (Denmark) Multivalent Vaccines Product and Service

    • 14.14 Sanofi Pasteur SA (France)

      • 14.14.1 Sanofi Pasteur SA (France) Company Details

      • 14.14.2 Sanofi Pasteur SA (France) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 Sanofi Pasteur SA (France) Multivalent Vaccines Product and Service

    • 14.15 Panacea Biotec (India)

      • 14.15.1 Panacea Biotec (India) Company Details

      • 14.15.2 Panacea Biotec (India) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

      • 14.15.3 Panacea Biotec (India) Multivalent Vaccines Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Multivalent Vaccines

    • Figure Multivalent Vaccines Picture

    • Table Global Multivalent Vaccines Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Multivalent Vaccines Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Multivalent Vaccines Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Multivalent Vaccines Consumption by Country (2017-2022)

    • Figure United States Multivalent Vaccines Consumption and Growth Rate (2017-2022)

    • Table Europe Multivalent Vaccines Consumption and Growth Rate (2017-2022)

    • Figure China Multivalent Vaccines Consumption and Growth Rate (2017-2022)

    • Figure Japan Multivalent Vaccines Consumption and Growth Rate (2017-2022)

    • Figure India Multivalent Vaccines Consumption and Growth Rate (2017-2022)

    • Figure South Korea Multivalent Vaccines Consumption and Growth Rate (2017-2022)

    • Figure Global Multivalent Vaccines Consumption Forecast by Country (2022-2028)

    • Figure United States Multivalent Vaccines Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Multivalent Vaccines Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Multivalent Vaccines Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Multivalent Vaccines Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Multivalent Vaccines Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Multivalent Vaccines Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Conjugate Vaccines Consumption and Growth Rate (2017-2022)

    • Figure Global Inactivated and Subunit Vaccines Consumption and Growth Rate (2017-2022)

    • Figure Global Live Attenuated Vaccines Consumption and Growth Rate (2017-2022)

    • Figure Global Toxoid Vaccines Consumption and Growth Rate (2017-2022)

    • Figure Global Recombinant Vaccines Consumption and Growth Rate (2017-2022)

    • Figure Global Pediatrics Consumption and Growth Rate (2017-2022)

    • Figure Global Adults Consumption and Growth Rate (2017-2022)

    • Figure Global Conjugate Vaccines Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Inactivated and Subunit Vaccines Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Live Attenuated Vaccines Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Toxoid Vaccines Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Recombinant Vaccines Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Pediatrics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Adults Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Multivalent Vaccines Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Multivalent Vaccines Export by Region (Top 5 Countries) (2017-2028)

    • Table GlaxoSmithKline, plc (UK) (Foundation Year, Company Profile and etc.)

    • Table GlaxoSmithKline, plc (UK) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline, plc (UK) Multivalent Vaccines Product and Service

    • Table Johnson & Johnson (US) (Foundation Year, Company Profile and etc.)

    • Table Johnson & Johnson (US) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

    • Table Johnson & Johnson (US) Multivalent Vaccines Product and Service

    • Table Protein Sciences Corporation (US) (Foundation Year, Company Profile and etc.)

    • Table Protein Sciences Corporation (US) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

    • Table Protein Sciences Corporation (US) Multivalent Vaccines Product and Service

    • Table CSL Limited (Australia) (Foundation Year, Company Profile and etc.)

    • Table CSL Limited (Australia) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

    • Table CSL Limited (Australia) Multivalent Vaccines Product and Service

    • Table Daiichi Sankyo (Japan) (Foundation Year, Company Profile and etc.)

    • Table Daiichi Sankyo (Japan) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

    • Table Daiichi Sankyo (Japan) Multivalent Vaccines Product and Service

    • Table Serum Institute of India Pvt Ltd (India) (Foundation Year, Company Profile and etc.)

    • Table Serum Institute of India Pvt Ltd (India) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

    • Table Serum Institute of India Pvt Ltd (India) Multivalent Vaccines Product and Service

    • Table Pfizer, Inc (US) (Foundation Year, Company Profile and etc.)

    • Table Pfizer, Inc (US) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer, Inc (US) Multivalent Vaccines Product and Service

    • Table Emergent BioSolutions, Inc (US) (Foundation Year, Company Profile and etc.)

    • Table Emergent BioSolutions, Inc (US) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

    • Table Emergent BioSolutions, Inc (US) Multivalent Vaccines Product and Service

    • Table MedImmune, LLC (US) (Foundation Year, Company Profile and etc.)

    • Table MedImmune, LLC (US) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

    • Table MedImmune, LLC (US) Multivalent Vaccines Product and Service

    • Table Merck & Co, Inc (US) (Foundation Year, Company Profile and etc.)

    • Table Merck & Co, Inc (US) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck & Co, Inc (US) Multivalent Vaccines Product and Service

    • Table Astellas Pharma Inc (Japan) (Foundation Year, Company Profile and etc.)

    • Table Astellas Pharma Inc (Japan) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

    • Table Astellas Pharma Inc (Japan) Multivalent Vaccines Product and Service

    • Table Mitsubishi Tanabe Pharma Corporation (Japan) (Foundation Year, Company Profile and etc.)

    • Table Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Product and Service

    • Table Bavarian Nordic (Denmark) (Foundation Year, Company Profile and etc.)

    • Table Bavarian Nordic (Denmark) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bavarian Nordic (Denmark) Multivalent Vaccines Product and Service

    • Table Sanofi Pasteur SA (France) (Foundation Year, Company Profile and etc.)

    • Table Sanofi Pasteur SA (France) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi Pasteur SA (France) Multivalent Vaccines Product and Service

    • Table Panacea Biotec (India) (Foundation Year, Company Profile and etc.)

    • Table Panacea Biotec (India) Multivalent Vaccines Sales, Price, Value and Gross Profit (2017-2022)

    • Table Panacea Biotec (India) Multivalent Vaccines Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US